The Long-Term Outlook: From Childhood to Adulthood
At a Glance
PCDH19-related epilepsy often becomes less active after age 10, but seizure clusters can recur and stopping anti-seizure medication has a high relapse risk. Long-term care should also support cognition, mental health, reproductive planning, and autonomy during the transition to adult services.
As individuals with PCDH19-related epilepsy grow, the focus of their care naturally shifts. While the early years are often dominated by the urgent management of seizure clusters, the long-term outlook is typically characterized by a “calming” of the epilepsy and an increasing focus on supporting development, mental health, and autonomy [1][2].
The Transition in Seizure Frequency
For many, the pre-teen years bring a significant change. Research has shown that seizure frequency often decreases markedly after age 10 to 10.5 years [1].
- Improving Patterns: By the time they reach adolescence or young adulthood, some patients may go years without a treated breakthrough seizure [3].
- The Persistence of Clusters: Even as daily seizures become less common, many individuals (nearly 80% in some studies) still experience at least occasional seizures or clusters throughout their lives [1].
- A “New Normal”: In adulthood, the primary medical challenge often shifts from stopping active seizures to managing the long-term cognitive and behavioral effects of the condition [2].
A Warning on Medication Withdrawal
Because seizures often improve naturally with age, it can be tempting to consider stopping anti-seizure medications (ASMs). However, this must be approached with extreme caution.
Evidence suggests that PCDH19-related epilepsy is highly sensitive to medication changes. In one retrospective series of 77 attempts to withdraw medication in selected seizure-free patients, the relapse rate was 88.3% [4]. Only about 2.6% of those patients were able to stay off medication entirely without seizures returning [4]. While this is cohort-specific evidence and must be balanced against adverse effects, it underscores the severe risk. Medication should never be stopped abruptly. Any supervised taper is a highly individualized decision that must be led by an epileptologist [4].
Persistent and Emerging Challenges
While the “electrical storms” of the brain may quiet down, the neurodevelopmental and psychiatric features often persist into adulthood. These can include:
- Executive Function: Challenges with planning, organization, and emotional control often become more noticeable as the person faces the demands of adult life [5].
- Psychiatric Health: There is a known risk for psychiatric issues, including psychosis (hallucinations or delusions), which can emerge during adolescence or early adulthood [6]. Approximately 21% of females aged 11 and older in one cohort experienced psychotic symptoms [6].
- Cognitive Support: Intellectual disability and autism spectrum features typically remain stable, meaning long-term support for communication and daily living is usually required [7][1].
Reproductive Health and Adulthood Planning
Transitioning to adult care requires direct counseling on reproductive health and genetics. Affected females have a 50% chance in each pregnancy of transmitting the variant. Furthermore, medications like valproate carry severe fetal risks (teratogenicity) if taken during pregnancy. Careful coordination with primary care, obstetric services, and genetic counselors is vital for contraception and pregnancy planning.
Building Your Long-Term Care Team
Managing the transition to adulthood requires more than just a neurologist. A multi-disciplinary team is the gold standard for ensuring the highest quality of life [2]. This team should ideally include:
- Epileptologist: To monitor for breakthrough clusters and manage medications safely.
- Psychiatrist: To screen for and treat emerging mood or psychotic symptoms [6].
- Neuropsychologist: To provide updated assessments of cognitive strengths and needs for vocational planning [7].
- Social Worker/Case Manager: To help navigate the complex transition to adult disability services, housing, and legal protections [8].
Transition planning should center the individual’s autonomy and preferences. Families should consult local legal experts regarding less restrictive alternatives to guardianship, such as supported decision-making, healthcare and financial powers of attorney, and special needs trusts, as adult services vary widely by jurisdiction [8].
Common questions in this guide
Do seizures usually get better as people with PCDH19-related epilepsy grow up?
Is it safe to stop seizure medicine after a long seizure-free period?
What long-term challenges can continue after seizures become less frequent?
What specialists are helpful during the transition to adult care?
What should families know about pregnancy and passing on PCDH19?
How can adulthood planning protect autonomy for someone with PCDH19-related epilepsy?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given the high relapse rate seen in cohorts, what specific clinical signs should we see before we even consider a trial of medication reduction?
- 2.How will the transition to adult care be managed to ensure psychiatric and behavioral needs are monitored as closely as seizures?
- 3.What is our long-term plan for managing 'breakthrough' clusters if they occur after a long period of seizure freedom?
- 4.Can we review reproductive counseling and teratogenicity (fetal risks) of the current daily medications we use?
- 5.Can you recommend a specialist familiar with supported decision-making and the risks of behavioral dysregulation in rare genetic epilepsies?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (8)
- 1
Defining the electroclinical phenotype and outcome of PCDH19-related epilepsy: A multicenter study.
Trivisano M, Pietrafusa N, Terracciano A, et al.
Epilepsia 2018; (59(12)):2260-2271 doi:10.1111/epi.14600.
PMID: 30451291 - 2
The Broad Clinical Spectrum of Epilepsies Associated With Protocadherin 19 Gene Mutation.
Dell'Isola GB, Vinti V, Fattorusso A, et al.
Frontiers in neurology 2021; (12()):780053 doi:10.3389/fneur.2021.780053.
PMID: 35111125 - 3
[Clinical characteristics of PCDH19-female limited epilepsy].
Chen Y, Yang XL, Liu AJ, et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics 2019; (57(11)):857-862 doi:10.3760/cma.j.issn.0578-1310.2019.11.008.
PMID: 31665840 - 4
Antiseizure medication withdrawal in seizure-free patients with PCDH19-related epilepsy: A multinational cohort survey.
Aledo-Serrano Á, Del Ser T, Gil-Nagel A
Seizure 2020; (80()):259-261 doi:10.1016/j.seizure.2020.06.007.
PMID: 32682289 - 5
Behavioral and neuropsychological profile of a male patient with mosaic PCDH19 mutation.
Johannessen M, Kjellsen IM, Malt E
Epilepsy & behavior reports 2022; (19()):100559 doi:10.1016/j.ebr.2022.100559.
PMID: 35860011 - 6
Schizophrenia is a later-onset feature of PCDH19 Girls Clustering Epilepsy.
Vlaskamp DRM, Bassett AS, Sullivan JE, et al.
Epilepsia 2019; (60(3)):429-440 doi:10.1111/epi.14678.
PMID: 30828795 - 7
PCDH19-related epilepsy is associated with a broad neurodevelopmental spectrum.
Smith L, Singhal N, El Achkar CM, et al.
Epilepsia 2018; (59(3)):679-689 doi:10.1111/epi.14003.
PMID: 29377098 - 8
A survey of adult caregivers of people with developmental and epileptic encephalopathies: A long-term care planning needs assessment.
Andrade DM, Bailey LD, Meskis MA, et al.
Epilepsy & behavior : E&B 2025; (172()):110677 doi:10.1016/j.yebeh.2025.110677.
PMID: 40886679
This page is for informational purposes and does not replace medical advice. Medication changes, pregnancy planning, and transition decisions for PCDH19-related epilepsy should be made with the treating specialists.
Get notified when new evidence is published on Female restricted epilepsy with intellectual disability.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.